Renalytix plc Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Renalytix plc (RENXF) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $2.76 million as of 2024-06-30, per its 10-K filed 2024-09-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2024-09-30
- 2024-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.76M.
- 2023-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.33M.
- 2022-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.02M.
- 2021-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $762.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2024-06-30 | $2.76M 10-K · filed 2024-09-30 |
| 2023-06-30 | $1.33M 10-K · filed 2024-09-30 |
| 2022-06-30 | $1.02M 10-K · filed 2023-09-28 |
| 2021-06-30 | $762.00K 20-F · filed 2022-10-31 |
| 2020-06-30 | $198.00K 20-F · filed 2022-10-31 |
| 2019-06-30 | $88.00K 20-F/A · filed 2022-08-01 |
| 2018-06-30 | $0.00 20-F/A · filed 2020-11-10 |